[Becky]

However - the 3 yr survival stats were stats that were dervived only from the 3 yr trial. Once the trial was done, that was it. What happened to these women in year 4 and 5 (when compared to counterparts who continued on hormone therapy). What were the stats on yr 4 versus women who were continuing therapy. Also, what was the comparison overall as all women took Lupron or Zoladex to shutdown the ovaries which may not happen in "real life" (especially to young women who are taking Tamoxifen).

Shutting down the ovaries in premenopausal women is a boon to survival (prior to Tamoxifen, removing ovaries greatly assisted survival and was commonly done - at least on women with mets).

As many of you know, the 100+ month stats on taking 5 yrs of Arimidex vs Tamoxifen is impressive. I wonder how 3 yrs will stack up (even though you are not comparing apples to apples since the 3 yr women also had ovarian suppression and the 5 yr women did not).

Also, if 3 yrs is worse, is that because they allowed premenopausal women's ovaries to pump out the estrogen again (with no added protection of Tamoxifen)? So many questions between both studies.